NK cells from patients with AML have been reported to exert CD16A-mediated ADCC activity29,30, demonstrating that CD16A-mediated NK cell cytotoxicity in AML patients is mostly conserved20,29,30. This evidence concerns the gene FCGR3A and acute myeloid leukemia.